8-K: Reviva Pharmaceuticals Announces Enrollment Update for Brilaroxazine Schizophrenia Study

Reviva Pharmaceuticals reports positive enrollment progress in its open-label extension study of brilaroxazine for schizophrenia, with topline data expected in December 2024.

Summary

• Reviva Pharmaceuticals has provided an update on its open-label extension (OLE) study of brilaroxazine for schizophrenia.
• The study is progressing well globally, with 108 patients completing one year of treatment and over 250 patients completing six months of treatment.
• Long-term safety data from 100 patients who have completed 12 months of treatment is a requirement for the New Drug Application (NDA) submission to the FDA.
• Topline data from the 1-year OLE trial is now expected in December 2024.
• The 12-month long-term safety study is expected to be completed in Q1 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong enrollment numbers and the collection of required safety data, but there are inherent risks in drug development, hence not a perfect score.

Positives

• The global trial is progressing well with strong enrollment numbers.
• Brilaroxazine continues to be generally well tolerated in patients with acute and stable schizophrenia.
• The company has collected the required long-term safety data for the NDA submission.
• The study is on track to complete the 12-month long-term safety study in Q1 2025.
• Positive topline data from the global Phase 3 RECOVER trial demonstrated statistically significant and clinically meaningful reductions across all major symptom domains.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's ability to raise sufficient funding is a risk factor.
• There are risks associated with product development, clinical and regulatory timelines, and expenses.

Future Outlook

The company anticipates reporting topline 12-month long-term safety and efficacy data in December 2024 and completing the 12-month long-term safety study in Q1 2025. They also intend to develop brilaroxazine for other neuropsychiatric indications.

Management Comments

• Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, stated that they are pleased with the pace of enrollment of the OLE study.
• He also noted that they have collected the long-term safety data required for the planned NDA submission to the FDA.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly companies focused on developing treatments for central nervous system disorders like schizophrenia. The progress of Reviva's brilaroxazine study is being closely watched by investors and competitors in the CNS therapeutic space.

Comparison to Industry Standards

• The enrollment numbers of 108 patients completing one year and over 250 completing six months are significant for a Phase 3 open-label extension study, indicating strong patient participation and interest in the treatment.
• The collection of long-term safety data from 100 patients is a critical step for NDA submission, aligning with standard regulatory requirements for new drug approvals.
• The expected topline data in December 2024 is a key milestone, and the timing is consistent with typical timelines for late-stage clinical trials.
• Companies like Alkermes (ALKS) and Intra-Cellular Therapies (ITCI) are also developing treatments for schizophrenia, and Reviva's progress will be compared against their clinical trial results and regulatory timelines.

Stakeholder Impact

• Shareholders will be interested in the progress of the clinical trial and the upcoming topline data.
• Patients with schizophrenia and their families may benefit from the development of brilaroxazine.
• The company's employees are working on the clinical trial and the regulatory submission process.
• The company's suppliers and partners are involved in the development and manufacturing of the drug.

Next Steps

• The company will report topline data from the 1-year open-label extension trial in December 2024.
• The company will complete the 12-month long-term safety study in Q1 2025.
• The company plans to submit a New Drug Application (NDA) to the FDA.

Key Dates

Keywords

brilaroxazine, schizophrenia, clinical trial, open-label extension, long-term safety, NDA, FDA, RECOVER trial, CNS, biomarkers